North American Deep Brain Stimulators Market Segmentation, Forecast, By 2025Posted by shibaomrglobal on February 7th, 2020 North American Deep Brain Stimulators market is expected to grow at a CAGR of 7.4% during the forecast period. Deep brain stimulation is a method to implant electrodes in a certain area of the brain. The electrodes generate electrical impulse which regulates abnormal impulses. A device similar to the pacemaker is implanted under the skin of the upper chest. The wire travels under the skin and connects device to the electrode to the brain. Also, it is approved by the US FDA to reduce seizures in difficult-to-treat epilepsy, whose symptoms cannot be controlled by the use of medication. It is minimally invasive and involves creating small holes in the skull to implant the electrodes. By surgery, batteries under the skin in the chest are implanted. To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/north-american-deep-brain-stimulators-market Deep brain stimulation reversibly alters the abnormal function of the brain tissue in the region of the stimulating electrode. Patient with moderate disability from Parkinson’s disease can opt for this surgery. An incidence of Parkinson’s disease is increasing considerably across the globe. In 2017, as per the Institute for Health Metrics and Evaluation, incidence of Parkinson’s disease was more than a million as compared to nearly 912,000 in 2013. Around 10 million people are living with Parkinson’s disease in 2019, globally. Some of the major companies working in the field of deep brain stimulation are Aleva Neurotherapeutics SA, Abbott Laboratories Incorporated, Boston Scientific Corporation, Cala Health, Incorporated, Functional Neuromodulation Limited, Livanova PLC, Medtronic PLC, Nevro Corporation, Nuvectra Corporation, Stimwave LLC and so on. The global market of deep brain stimulator is expected to reach .8 billion in 2025 as compared to .1 billion in 2018 with a CAGR of 7.2% during the forecast period. In February 2019, Medtronic PLC launched deep brain stimulation for medically refractory epilepsy. The product was launched after pre-market approval from the US FDA for epilepsy as an adjunctive treatment for reducing the frequency of partial-onset seizures in individuals over 18 years of age. The US FDA approved it, based on the results from the SANTE (Stimulation of the anterior nucleus of the thalamus in epilepsy) trial. Browse the full report description North American Deep Brain Stimulators Market at https://www.omrglobal.com/industry-reports/north-american-deep-brain-stimulators-market North American Deep Brain Stimulators Market-Segmentation By Product
By Applications
By End-Users
Company Profiles
About us: Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Like it? Share it! More by this author |